What is the role of erythropoietin in patients with solid tumours?

Annals of Oncology

Volumn 9, Issue 3, 1998, Pages 239-241

  Maraveyas, A ^a   Pettengell, R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; DOSE RESPONSE; EDITORIAL; GRAFT VERSUS HOST REACTION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SOLID TUMOR;

ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 0031976977     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1023/a:1008273032715     Document Type: Editorial

References (18)

1. Miller CB. Jones RJ. Piantadosi et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 332. 1689-92.
2. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994; 84: 997-1004.
3. Cascinu S, Fedeli A, Del Ferro E et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized double-blind trial with placebo. J Clin Oncol 1994: 12: 1058-62.
4. Platanias LC. Miller CB, Mick R et al. Treatment of chemotherapy- induced anemia in cancer patients with recombinant erythropoietin. J Clin Oncol 1991: 9: 2021-6.
5. Ludwig H. Sundal E, Pecherstorfer M et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995; 76: 2319-29.
6. ten Bokkel-Huinink WW. Controlled multicenter study of the influence of two different dosages of subcutaneous rhEPO on the development of anemia and transfusion dependancy in patients with ovarian carcinoma treated with platinum-based combination chemotherapy. In Smyth JF, Boogaerts MA, Ehmer BR-M (eds): rhErythropoietin in Cancer Supportive Treatment. New York: Marcel Dekker 1996: 99-112.
7. Cazzola M. Mercuriali F. Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89: 4248-67.
8. Ludwig H, Fritz E. Leitgeb C et al. Prediction of response to erythropoietin treatment in chronic anemia. Blood 1994; 84: 1056-63.
9. Case DC, Bukowski RM, Carey RW et al. Recombinant human erythropoietin therapy for anaemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85: 801-6.
10. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anaemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73: 2535-42.
11. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218-34.
12. Mohandas K, Aledort L. Transfusion requirements, risks and costs for patients with malignancy. Transfusion 1995; 35: 427-30.
13. Barosi G, Liberato NL. The cost-effectiveness of rhuEPO use in anemia of cancer. In Smyth JF, Boogaerts MA, Ehmer BR-M (eds): rhErythropoietin in Cancer Supportive Treatment. New York: Marcel Dekker 1996: 45-57.
14. Sheffield R, Sullivan SD. Saltiel E. Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anaemia. Ann Pharmacother 1997; 31: 15-22.
15. Cash JD. Problems of providing a national blood-transfusion service. In Smyth JF. Boogaerts MA. Ehmer BR-M (eds). rhErythropoietin in Cancer Supportive Treatment. New York: Marcel Dekker 1996; 59-66.
16. Oberhof T C, Neri B, Amadori D et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study. Ann Oncol 1998; 9 (3). 255-60 (this issue).
17. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-huEPO/Epoetin-a) therapy in cancer patients Blood 1995; 85: 1676-8
18. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies Semin Oncol 1994; 21: 21-8.